Investigation into ADMA Biologics Securities Litigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: PRnewswire
- Lawsuit Investigation: Faruqi & Faruqi, LLP is investigating potential securities fraud claims against ADMA Biologics, urging investors who suffered losses between August 9, 2024, and March 25, 2026, to contact the firm by the August 10, 2026 deadline to discuss their legal rights.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics and its executives violated federal securities laws by failing to disclose related party transactions, using channel stuffing to create a false appearance of revenue growth, and lacking adequate internal controls, which misled investors about the company's business and financial health.
- Stock Price Volatility: Following these allegations, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating severe market concerns regarding the company's financial stability.
- Investor Participation Opportunity: Affected investors can participate in the class action through Faruqi & Faruqi and may seek lead plaintiff status, although choosing not to do so will not affect their eligibility for any potential recovery, highlighting the importance of legal consultation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into ADMA Biologics Securities Litigation
- Lawsuit Investigation: Faruqi & Faruqi, LLP is investigating potential securities fraud claims against ADMA Biologics, urging investors who suffered losses between August 9, 2024, and March 25, 2026, to contact the firm by the August 10, 2026 deadline to discuss their legal rights.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics and its executives violated federal securities laws by failing to disclose related party transactions, using channel stuffing to create a false appearance of revenue growth, and lacking adequate internal controls, which misled investors about the company's business and financial health.
- Stock Price Volatility: Following these allegations, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating severe market concerns regarding the company's financial stability.
- Investor Participation Opportunity: Affected investors can participate in the class action through Faruqi & Faruqi and may seek lead plaintiff status, although choosing not to do so will not affect their eligibility for any potential recovery, highlighting the importance of legal consultation.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply to be lead plaintiff by August 10, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing, which led to investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, highlighting its leadership in the field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in securities class actions, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Notice of Class Action Lawsuit Against ADMA Biologics
- Class Action Timeline: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, that they must apply to be lead plaintiff by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false and misleading statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resources in this field, urging investors to choose counsel with a proven track record.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, although they are not represented by counsel until the class is certified.
See More
ADMA Biologics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a class action lawsuit for securities fraud, filed on behalf of investors who purchased shares between August 9, 2024, and March 25, 2026, alleging significant misstatements and omissions in financial reporting that undermine investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and utilized channel stuffing to inflate revenue figures, lacking adequate internal controls, which misled shareholders regarding the company's business prospects and could lead to substantial financial losses.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting serious market concerns about the company's financial transparency and operational integrity.
- Investor Action: Investors are urged to file for lead plaintiff status by August 10, 2026, to represent the class in the lawsuit, with KTMC offering free case evaluations, highlighting the rights of investors in such litigation and the potential for economic recovery.
See More
Investor Class Action Lawsuit Reminder
- Via Transportation Lawsuit: A class action lawsuit against Via Transportation, Inc. alleges that during the period from September 9, 2025, to June 9, 2026, the company failed to disclose declining annual recurring revenue per customer and regulatory issues, misleading investors about its business prospects, with a lead plaintiff deadline of August 10, 2026.
- Zillow Lawsuit: Zillow Group, Inc. faces a class action lawsuit claiming that from February 11, 2025, to May 7, 2026, it misrepresented its agreement with Redfin as a partnership rather than an acquisition, increasing regulatory scrutiny risks, with a lead plaintiff deadline of August 10, 2026.
- ADMA Lawsuit: ADMA Biologics, Inc. is under a class action lawsuit alleging undisclosed related party transactions and revenue manipulation from August 9, 2024, to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.
- Legal Consultation Opportunity: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact them for legal advice to protect their rights, emphasizing the importance of timely action in these class actions.
See More
ADMA Biologics Faces Securities Class Action Over Internal Control Failures
- Internal Control Failures: ADMA Biologics allegedly certified its disclosure controls as effective across seven SEC filings from August 2024 to March 2026, while the lawsuit claims these certifications were false due to the simultaneous operation of a channel stuffing scheme and undisclosed related party transactions.
- Fictitious Revenue Growth: A March 2026 research report alleged that ADMA's reported 20% revenue growth was fabricated, estimating actual growth at negative 3%, which directly impacted investor perceptions of the company's financial health and led to a significant stock price decline.
- Concealed Related Party Transactions: The lawsuit asserts that while ADMA disclosed purchases from
See More
Investigation into ADMA Biologics Securities Litigation
- Lawsuit Investigation: Faruqi & Faruqi, LLP is investigating potential securities fraud claims against ADMA Biologics, urging investors who suffered losses between August 9, 2024, and March 25, 2026, to contact the firm by the August 10, 2026 deadline to discuss their legal rights.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics and its executives violated federal securities laws by failing to disclose related party transactions, using channel stuffing to create a false appearance of revenue growth, and lacking adequate internal controls, which misled investors about the company's business and financial health.
- Stock Price Volatility: Following these allegations, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating severe market concerns regarding the company's financial stability.
- Investor Participation Opportunity: Affected investors can participate in the class action through Faruqi & Faruqi and may seek lead plaintiff status, although choosing not to do so will not affect their eligibility for any potential recovery, highlighting the importance of legal consultation.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply to be lead plaintiff by August 10, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing, which led to investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, highlighting its leadership in the field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in securities class actions, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Notice of Class Action Lawsuit Against ADMA Biologics
- Class Action Timeline: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, that they must apply to be lead plaintiff by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false and misleading statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resources in this field, urging investors to choose counsel with a proven track record.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, although they are not represented by counsel until the class is certified.
See More
ADMA Biologics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a class action lawsuit for securities fraud, filed on behalf of investors who purchased shares between August 9, 2024, and March 25, 2026, alleging significant misstatements and omissions in financial reporting that undermine investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and utilized channel stuffing to inflate revenue figures, lacking adequate internal controls, which misled shareholders regarding the company's business prospects and could lead to substantial financial losses.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting serious market concerns about the company's financial transparency and operational integrity.
- Investor Action: Investors are urged to file for lead plaintiff status by August 10, 2026, to represent the class in the lawsuit, with KTMC offering free case evaluations, highlighting the rights of investors in such litigation and the potential for economic recovery.
See More
Investor Class Action Lawsuit Reminder
- Via Transportation Lawsuit: A class action lawsuit against Via Transportation, Inc. alleges that during the period from September 9, 2025, to June 9, 2026, the company failed to disclose declining annual recurring revenue per customer and regulatory issues, misleading investors about its business prospects, with a lead plaintiff deadline of August 10, 2026.
- Zillow Lawsuit: Zillow Group, Inc. faces a class action lawsuit claiming that from February 11, 2025, to May 7, 2026, it misrepresented its agreement with Redfin as a partnership rather than an acquisition, increasing regulatory scrutiny risks, with a lead plaintiff deadline of August 10, 2026.
- ADMA Lawsuit: ADMA Biologics, Inc. is under a class action lawsuit alleging undisclosed related party transactions and revenue manipulation from August 9, 2024, to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.
- Legal Consultation Opportunity: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact them for legal advice to protect their rights, emphasizing the importance of timely action in these class actions.
See More
ADMA Biologics Faces Securities Class Action Over Internal Control Failures
- Internal Control Failures: ADMA Biologics allegedly certified its disclosure controls as effective across seven SEC filings from August 2024 to March 2026, while the lawsuit claims these certifications were false due to the simultaneous operation of a channel stuffing scheme and undisclosed related party transactions.
- Fictitious Revenue Growth: A March 2026 research report alleged that ADMA's reported 20% revenue growth was fabricated, estimating actual growth at negative 3%, which directly impacted investor perceptions of the company's financial health and led to a significant stock price decline.
- Concealed Related Party Transactions: The lawsuit asserts that while ADMA disclosed purchases from
See More
